Aileron Therapeutics, Inc. (ALRN)
Aileron Therapeutics, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Boston, MA, US. The stock last traded at $2.11, up 9.33% on the session, giving a market capitalisation of $45.7M. On trailing twelve-month figures it carries a trailing P/E of -1.11, a net margin of 0.0%. Its beta of 2.34 implies it has historically moved more than the broad market.
Aileron Therapeutics, Inc. is a U.S.-based clinical-stage company specializing in chemoprotection oncology. Its primary therapeutic candidate, ALRN-6924, is currently being evaluated across multiple clinical trials for various cancer types. These include a Phase 1 trial for solid tumors and lymphoma, a Phase 2a clinical trial targeting peripheral T-cell lymphoma, and a Phase I trial for acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS). Furthermore, ALRN-6924 is involved in combination studies: a Phase 1b trial testing its efficacy with cytarabine (Ara-C) in patients with MDS, and a Phase 2a combination trial with palbociclib for individuals with tumors exhibiting MDM2 amplifications co-amplifications, as well as for those with p53-mutated small cell lung cancer (the latter having already completed its Phase 1b clinical assessment). The company maintains license agreements with institutions such as the Dana-Farber Cancer Institute, Harvard College, and Umicore Precious Metals Chemistry USA, LLC. Established in 2001, the Boston, Massachusetts-headquartered firm was originally known as Renegade Therapeutics, Inc. before rebranding to Aileron Therapeutics, Inc. in February 2007.
Aileron Therapeutics, Inc. is most often compared with the following Healthcare names: